Tonix presents phase 1 data for Lyme disease prevention drug TNX-4800

March 31, 2026 7:01 AM

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented phase 1 clinical trial data for TNX-4800, a monoclonal antibody designed to prevent ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found